| scholarly article | Q13442814 |
| P2093 | author name string | Qiang Liu | |
| Juan Zhang | |||
| P2860 | cites work | Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms | Q33851318 |
| Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry | Q33947437 | ||
| Brain cholesterol: long secret life behind a barrier. | Q33975527 | ||
| Hydroxylated and non-hydroxylated sulfatide are distinctly distributed in the human cerebral cortex | Q33975942 | ||
| Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis | Q34007818 | ||
| ABC transporters in cellular lipid trafficking | Q34069104 | ||
| Altered cholesterol and fatty acid metabolism in Huntington disease | Q34080706 | ||
| The human ATP-binding cassette (ABC) transporter superfamily. | Q34083168 | ||
| A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease | Q34094305 | ||
| Cholesterol reduction impairs exocytosis of synaptic vesicles | Q34094964 | ||
| Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. | Q34096644 | ||
| Intramembrane proteolysis by presenilins | Q34185772 | ||
| Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight | Q34216658 | ||
| The emerging field of lipidomics | Q34438156 | ||
| Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: implications for Alzheimer's disease | Q34489852 | ||
| Complete characterization of the human ABC gene family. | Q34502446 | ||
| Statins and the risk of dementia | Q34511970 | ||
| Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo | Q34514599 | ||
| ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. | Q34556413 | ||
| Niemann-Pick type C pathogenesis and treatment: from statins to sugars. | Q34632493 | ||
| Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons | Q34663462 | ||
| Lipoprotein receptors in the nervous system | Q34667437 | ||
| Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3. | Q34691497 | ||
| Informatics and computational strategies for the study of lipids. | Q34739639 | ||
| Role of glia-derived cholesterol in synaptogenesis: new revelations in the synapse-glia affair. | Q35006315 | ||
| Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family | Q35023109 | ||
| Cholesterol homeostasis and function in neurons of the central nervous system | Q35178066 | ||
| Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex | Q35218379 | ||
| Plasmalogens, docosahexaenoic acid and neurological disorders. | Q35624458 | ||
| Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of synthetic ceramide analogues | Q35676462 | ||
| Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein | Q35732556 | ||
| Linking lipids to Alzheimer's disease: cholesterol and beyond | Q35875480 | ||
| Lipids in membrane protein structures | Q35935371 | ||
| Cholesterol and amyloid beta fibrillogenesis | Q36040341 | ||
| The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. | Q46738144 | ||
| Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. | Q46763324 | ||
| Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia | Q46849745 | ||
| Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes | Q46866662 | ||
| Deletion of the transmembrane transporter ABCG1 results in progressive pulmonary lipidosis | Q46885802 | ||
| Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration | Q48154082 | ||
| Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease | Q48159810 | ||
| Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). | Q48164740 | ||
| The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease | Q48254282 | ||
| Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats | Q48256982 | ||
| Sialylated human apolipoprotein E (apoEs) is preferentially associated with neuron-enriched cultures from APOE transgenic mice | Q48263418 | ||
| Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease | Q48321246 | ||
| Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain | Q48394369 | ||
| Liver X receptor activation restores memory in aged AD mice without reducing amyloid | Q48487098 | ||
| Cortical distribution of gangliosides in Alzheimer's disease | Q48505046 | ||
| Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition | Q48601482 | ||
| Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study | Q48874488 | ||
| The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice | Q48890273 | ||
| Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease | Q48901597 | ||
| Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. | Q50715903 | ||
| The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. | Q51955851 | ||
| The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. | Q52086849 | ||
| Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. | Q52366724 | ||
| Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. | Q52937381 | ||
| Brain gangliosides in dementia of the Alzheimer type. | Q53188661 | ||
| Neural membrane phospholipids in Alzheimer disease. | Q53213229 | ||
| Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. | Q53236302 | ||
| Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. | Q53236904 | ||
| Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. | Q53303473 | ||
| Oleic acid ameliorates amyloidosis in cellular and mouse models of Alzheimer's disease | Q53314166 | ||
| Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. | Q53422871 | ||
| Age-related changes in brain mitochondrial DNA deletion and oxidative stress are differentially modulated by dietary fat type and coenzyme Q₁₀. | Q54386891 | ||
| Clinical and pathological correlates of apolipoprotein E ?4 in Alzheimer's disease | Q57620860 | ||
| Lipidomics: coming to grips with lipid diversity | Q57959842 | ||
| Human apolipoprotein E. The complete amino acid sequence | Q70312109 | ||
| Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions | Q70478363 | ||
| Neurofibrillary tangles in Niemann-Pick disease type C | Q72641450 | ||
| The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation | Q73279880 | ||
| Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients | Q73462725 | ||
| Measurement of apolipoprotein E (apoE) in cerebrospinal fluid | Q73818777 | ||
| Role of lipoproteins in the delivery of lipids to axons during axonal regeneration | Q73919813 | ||
| Inflammatory processes in Alzheimer's disease | Q79557863 | ||
| Sphingolipid metabolites in neural signalling and function | Q81077831 | ||
| Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway | Q83180434 | ||
| Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models | Q21135583 | ||
| Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease | Q22248091 | ||
| Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease | Q24308731 | ||
| A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease | Q24531755 | ||
| Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy | Q24604376 | ||
| ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models | Q24628845 | ||
| Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions | Q24648717 | ||
| Lipid rafts, cholesterol, and the brain | Q24655761 | ||
| Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1 | Q24672149 | ||
| Cholesterol, statins, and Alzheimer disease | Q24805492 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Alzheimer's disease: the cholesterol connection | Q28186482 | ||
| Role of ABCG1 and other ABCG family members in lipid metabolism | Q28190735 | ||
| Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression | Q28199385 | ||
| A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis | Q28199913 | ||
| Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation | Q28210028 | ||
| Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease | Q28238269 | ||
| Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database | Q28280965 | ||
| Alterations of phospholipid metabolites in postmortem brain from patients with Alzheimer's disease | Q28322151 | ||
| Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease | Q28386524 | ||
| Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain | Q28506441 | ||
| Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus | Q28566058 | ||
| Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide | Q28568454 | ||
| LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins | Q28595076 | ||
| Cyclooxygenases 1 and 2 | Q29615645 | ||
| Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance | Q30274556 | ||
| Role of phosphatidylinositol(4,5)bisphosphate organization in membrane transport by the Unc104 kinesin motor | Q30493987 | ||
| Cholesterol-dependent modulation of tau phosphorylation in cultured neurons | Q32034732 | ||
| Deregulation of sphingolipid metabolism in Alzheimer's disease | Q33693061 | ||
| Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons | Q33762153 | ||
| Statins--a cure-all for the brain? | Q36085649 | ||
| Lipid signaling in neural plasticity, brain repair, and neuroprotection | Q36217327 | ||
| Cellular lipidomics | Q36247057 | ||
| Cholesterol in Alzheimer's disease | Q36317585 | ||
| Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway | Q36321788 | ||
| Role of cholesterol in amyloid cascade: cholesterol-dependent modulation of tau phosphorylation and mitochondrial function | Q36546479 | ||
| Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease | Q36604677 | ||
| Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease | Q36613756 | ||
| Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. | Q36658177 | ||
| Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide | Q36773735 | ||
| Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease | Q36836935 | ||
| A neuroscientist's guide to lipidomics. | Q36946556 | ||
| Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. | Q36974939 | ||
| Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. | Q36983897 | ||
| Fatting the brain: a brief of recent research | Q37155461 | ||
| Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease | Q37328906 | ||
| Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection | Q37374235 | ||
| Oxysterols and neurodegenerative diseases. | Q37402910 | ||
| Therapeutic potential of statins in Alzheimer's disease. | Q37423422 | ||
| Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. | Q37469703 | ||
| Cholesterol and statins in Alzheimer's disease: current controversies | Q37603783 | ||
| Studies on plasmalogen-selective phospholipase A2 in brain | Q37668193 | ||
| Statins: multiple neuroprotective mechanisms in neurodegenerative diseases | Q37734640 | ||
| Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. | Q37894181 | ||
| Inflammation in the early stages of neurodegenerative pathology | Q37912590 | ||
| Alzheimer disease in 2020. | Q38057724 | ||
| Organellar lipidomics--background and perspectives | Q38100905 | ||
| Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism | Q38391849 | ||
| Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands | Q39647439 | ||
| ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. | Q40339567 | ||
| Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. | Q40482351 | ||
| GM1 ganglioside regulates the proteolysis of amyloid precursor protein | Q40571948 | ||
| Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity | Q40631665 | ||
| Expression of Liver X Receptor Target Genes Decreases Cellular Amyloid β Peptide Secretion | Q40646962 | ||
| Promotion of tau phosphorylation by MAP kinase Erk1/2 is accompanied by reduced cholesterol level in detergent-insoluble membrane fraction in Niemann-Pick C1-deficient cells. | Q40668515 | ||
| Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide | Q40777105 | ||
| Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid | Q40807391 | ||
| Apolipoprotein E alleles as risk factors in Alzheimer's disease | Q41036434 | ||
| Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein | Q41150323 | ||
| Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease | Q41159549 | ||
| Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens | Q41454656 | ||
| Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration | Q42032902 | ||
| Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. | Q42524390 | ||
| Structural insight into the differential effects of omega-3 and omega-6 fatty acids on the production of Abeta peptides and amyloid plaques | Q42692193 | ||
| Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex | Q43181451 | ||
| Long-term effects of high lipid and high energy diet on serum lipid, brain fatty acid composition, and memory and learning ability in mice | Q43218534 | ||
| Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease | Q43244604 | ||
| Brain membrane phospholipid alterations in Alzheimer's disease | Q43743686 | ||
| CNS synaptogenesis promoted by glia-derived cholesterol | Q43794738 | ||
| Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains | Q43889089 | ||
| Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis | Q44163309 | ||
| Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. | Q44185145 | ||
| Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study | Q44201251 | ||
| Novel role for apolipoprotein E in the central nervous system. Modulation of sulfatide content | Q44261820 | ||
| Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis | Q44370232 | ||
| Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease | Q44536587 | ||
| Specificity and potential mechanism of sulfatide deficiency in Alzheimer's disease: an electrospray ionization mass spectrometric study | Q44607988 | ||
| Genetic study evaluating LDLR polymorphisms and Alzheimer's disease | Q44637758 | ||
| APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. | Q44657566 | ||
| ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. | Q44989710 | ||
| Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients | Q45056703 | ||
| Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. | Q45992629 | ||
| ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation | Q46265206 | ||
| Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron | Q46505506 | ||
| P433 | issue | 2 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 331-345 | |
| P577 | publication date | 2014-04-15 | |
| P1433 | published in | Neuroscience Bulletin | Q15764540 |
| P1476 | title | Lipid metabolism in Alzheimer's disease | |
| P478 | volume | 30 |
| Q64108193 | Altered Lipidome Composition Is Related to Markers of Monocyte and Immune Activation in Antiretroviral Therapy Treated Human Immunodeficiency Virus (HIV) Infection and in Uninfected Persons |
| Q36913723 | Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. |
| Q42347359 | Alzheimer's disease: from molecule to clinic |
| Q60949291 | Association of gut microbiota composition and function with a senescence-accelerated mouse model of Alzheimer's Disease using 16S rRNA gene and metagenomic sequencing analysis |
| Q64110438 | Comparison of the systemic phospholipid profile in dogs diagnosed with idiopathic inflammatory bowel disease or food-responsive diarrhea before and after treatment |
| Q92517995 | Evidence in support of chromosomal sex influencing plasma based metabolome vs APOE genotype influencing brain metabolome profile in humanized APOE male and female mice |
| Q64911453 | Genetic heterogeneity of Alzheimer's disease in subjects with and without hypertension. |
| Q60910191 | Genome-wide analysis of genetic predisposition to Alzheimer's disease and related sex disparities |
| Q89824008 | Metabolism: A Novel Shared Link between Diabetes Mellitus and Alzheimer's Disease |
| Q38840105 | Molecular Mechanisms of Vascular Dementia: What Can Be Learned from Animal Models of Chronic Cerebral Hypoperfusion? |
| Q91246348 | Nutrients in Alzheimer's Disease: The Interaction of Diet, Drugs and Disease |
| Q91819996 | Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy |
| Q59808077 | The hidden variables problem in Alzheimer's disease clinical trial design |
Search more.